针对MASH的Resmetirom:对一种新型治疗前沿的全面审查
Angad Tiwari1, Ashish Sharma2, Harendra Kumar3
1Department of Internal Medicine, Maharani Laxmi Bai Medical College, Jhansi 284001, Uttar Pradesh, India.
Biomedicines
|September 27, 2025
概括
新的MASH治疗方法Resmetirom通过激活甲状腺激素受体β来向肝脏脂肪和纤维化. 它提供代谢效益,但需要政策改革,以实现公平的患者获取和组合疗法研究.
科学领域:
- 肝病学和内分泌学.
- 代谢综合征研究 代谢综合征研究
- 药理学和治疗学 药理学和治疗学
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 是一种进展性肝病,与代谢综合征的组成部分,如2型糖尿病和肥胖症有关.
- 目前,带有纤维化的非脊髓炎性MASH的治疗选择有限,造成了大量未满足的医疗需求.
研究的目的:
- 审查最近FDA批准的resmetirom,这是治疗轻度至晚期纤维化非脊髓炎MASH的第一个治疗方法.
- 讨论作用机制,潜在的组合疗法以及临床应用和患者获取方面的挑战.
主要方法:
- 审查临床试验数据和resmetirom.com最近的监管批准.
- 分析resmetirom在改善脂质代谢和减少肝脏病理方面的作用机制.
- 讨论临床影响,包括组合策略和接入障碍.
主要成果:
- 选择性甲状腺激素受体-β激动剂Resmetirom于2024年获得FDA批准,用于纤维化MASH.
- 它增强肝脏β-氧化和脂质代谢,减少肝脏脂肪,炎症和纤维化,系统性影响最小.
- 结合生活方式干预和其他药物 (例如GLP-1激动剂,SGLT2抑制剂) 的联合治疗显示出有前途.
结论:
- Resmetirom代表了MASH管理的重大进步,提供了有针对性的治疗效益.
- 通过政策改革,提供者教育和定义的付款人终点来解决接入障碍,对于公平的接纳至关重要.
- 对组合疗法和成本效益的进一步研究将优化resmetirom的临床效用.
关键词:
MASH (与代谢功能障碍相关的脂肪肝炎)脱脂血症 (dyslipidaemia) 是一种疾病,肝脏纤维化 肝脏纤维化代谢综合征代谢综合征肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖这里是resmetiromirom的位置.更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
7.6K
11:02Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
1.1K
相关概念视频
01:22Myocarditis IV: Nursing Management
207
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
207
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
588
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
588
01:26Nephrotic Syndrome II : Assessment and Medical Management
201
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
201
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:16Therapeutic Drug Monitoring: Overview and Classification
309
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
309
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
602
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
602